R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, FASCO

Research Program

Discovery and Developmental Therapeutics
Phone Number

404-778-4381
Email Address

rdharve@emory.edu

Biography

R. Donald Harvey, PharmD, is a professor in the Department of Hematology and Medical Oncology with a joint appointment in the Department of Pharmacology and Chemical Biology at Emory University School of Medicine. A board-certified oncology pharmacist, Dr. Harvey serves as vice president of clinical research and executive director of Woodruff Industry Sponsored Clinical Trials at the Woodruff Health Sciences Center.

Dr. Harvey previously served as director of Winship Cancer Institute's Phase I Clinical Trials Unit and played a key role in the unit's opening in 2009 and subsequent expansion in 2018. He also served as medical director of Winship's Clinical Trials Office, where he worked to ensure the quality and compliance of clinical research practices at all Winship locations.

Dr. Harvey is a member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute. He has established an active clinical pharmacology research program in cancer at Emory with the goal of using pharmacokinetic, pharmacodynamic and other tools to improve individualization of therapy and clinical outcomes. An active principal and co-investigator on multiple trials, he also consults on experimental design of preclinical and clinical studies with a focus on optimizing correlative measures. Specific areas of research interest include agent tolerability and disposition in renal and hepatic impairment, effects of novel immunotherapeutics on hepatic metabolism, and use of therapeutic drug monitoring for anticancer agents.

Education

Dr. Harvey obtained his BS Pharmacy and Doctor of Pharmacy degrees at the University of North Carolina at Chapel Hill (UNC). He completed subsequent training at the University of Kentucky Medical Center and School of Pharmacy and specialized in Hematology/Oncology at UNC, where he was on staff and faculty for 8 years prior to coming to Grady Hospital in Atlanta where he served as a clinical specialist in hematology and oncology and director of the hematology and oncology residency program.

Titles & Roles

Professor, Department of Hematology and Medical Oncology

Emory University School of Medicine
Professor, Department of Pharmacology and Chemical Biology

Emory University School of Medicine
Executive Director, Woodruff Industry Sponsored Clinical Trials

Woodruff Health Sciences Center
Vice President, Clinical Research

Woodruff Health Sciences Center

Professional Memberships

Dr. Harvey is active nationally and internationally in several cancer and pharmacology professional organizations. He is a Fellow of the American College of Clinical Pharmacy, a Fellow of the Hematology/Oncology Pharmacy Association and a Fellow of the American Society of Clinical Oncology. He is a past president of the Hematology and Oncology Pharmacy Association, an international professional organization.

Research

Dr. Harvey's research interests include the clinical application of pharmacokinetic, pharmacodynamic and pharmacogenomic data to patient care.

View Current Clinical Trials


A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas Phase I/II Conditions Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma Location Winship Cancer Institute

Publications

Dr. Harvey is widely published in peer-reviewed journals.

Title/Journal	Authors	Publication Date
Improving Access to Patient-Focused, Decentralized Clinical Trials Requires Streamlined Regulatory Requirements: An ASCO Research Statement. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	R Thota, PA Hurley, TM Miller, SS Bruinooge, C Lipset, RD Harvey, LJ Black, A Dinsdale, JK Merrill, T Pollastro, SA Prindiville, MA Rizvi, S Sherwood, GS Nowakowski	11/20/2024
Bisbiguanide analogs induce mitochondrial stress to inhibit lung cancer cell invasion. iScience	CM Knippler, JL Arnst, IE Robinson, V Matsuk, TO Khatib, RD Harvey, M Shanmugam, JK Mouw, H Fu, T Ganesh, AI Marcus	04/19/2024
A call to action to advance patient-focused and decentralized clinical trials. Cancer	RD Harvey, TM Miller, PA Hurley, R Thota, LJ Black, SS Bruinooge, LM Boehmer, ME Fleury, J Kamboj, MA Rizvi, BE Symington, WD Tap, DM Waterhouse, LA Levit, JK Merrill, SA Prindiville, T Pollastro, JR Brewer, LP Byatt, L Hamroun, ES Kim, N Holland, GS Nowakowski	04/15/2024
A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors. Cancer medicine	D Juric, M Barve, U Vaishampayan, D Roda, A Calvo, NM Jañez, J Trigo, A Greystoke, RD Harvey, AJ Olszanski, M Opyrchal, A Spira, F Thistlethwaite, B Jiménez, JH Sappal, K Kannan, J Riley, C Li, C Li, RC Gregory, H Miao, S Wang	03/01/2024
A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors. Clinical therapeutics	G Falchook, A Patnaik, DL Richardson, RD Harvey, MR Sharma, N Hafez, E Hamilton, SA Piha-Paul, M Barve, T Wise-Draper, MR Patel, A Dowlati, J Pascuzzo, SC Tang, C Faltermeier, IA Malinowska, L Shtessel, A Striha, E Potocka	03/01/2024
Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research	BA Carneiro, L Cavalcante, D Mahalingam, A Saeed, H Safran, WW Ma, AL Coveler, S Powell, B Bastos, E Davis, V Sahai, W Mikrut, J Longstreth, S Smith, T Weisskittel, H Li, BA Borden, RD Harvey, S Sahebjam, A Cervantes, A Koukol, AP Mazar, N Steeghs, R Kurzrock, FJ Giles, P Munster	02/01/2024
Shifting Sociodemographic Characteristics of a Phase I Clinical Trial Population at an NCI-Designated Comprehensive Cancer Center in the Southeast. The oncologist	CS Lalonde, JM Switchenko, M Behera, MA Bilen, TK Owonikoko, JL Kaufman, AK Nooka, CM Lewis, E Hitron, H Collins, EC Judson, OB Alese, R Donald Harvey, JW Carlisle	12/11/2023
Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib Induction. JCO oncology practice	LF Sun, KT Maples, KH Hall, Y Liu, Y Cao, NS Joseph, CC Hofmeister, JL Kaufman, M Dhodapkar, AK Nooka, S Lonial, RD Harvey	09/01/2023
Debunking Sex and Disentangling Gender From Oncology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	AB Alpert, L Rivers, C Manzano, R Ruddick, S Adams, J Obedin-Maliver, RD Harvey, JJ Griggs, D Operario	08/01/2023
A phase 1 study of simvastatin in combination with topotecan and cyclophosphamide in pediatric patients with relapsed and/or refractory solid and CNS tumors. Pediatric blood & cancer	T Cash, HC Jonus, M Tsvetkova, JH Beumer, A Sadanand, JY Lee, CJ Henry, D Aguilera, RD Harvey, KC Goldsmith	08/01/2023
The earlier the better? Or better late than never? Dose optimization in oncology. Journal of the National Cancer Institute	RD Harvey	05/08/2023
Race-free renal function estimation equations and potential impact on Black patients: Implications for cancer clinical trial enrollment. Cancer	BN Schmeusser, AR Palacios, ER Midenberg, R Nabavizadeh, DH Patil, RD Harvey, J Bryksin, MJ Connor, K Ogan, MA Bilen, VA Master	03/15/2023
Improving oncology first-in-human and Window of opportunity informed consent forms through participant feedback. BMC medical ethics	AM Avinger, HC Sibold, G Campbell, E Abernethy, J Bourgeois, T McClary, S Blee, M Dixon, RD Harvey, RD Pentz	02/19/2023
Chemotherapy dosing in older adults with cancer: One size does NOT fit all. Journal of geriatric oncology	GR Williams, D Outlaw, RD Harvey, SM Lichtman, WC Zamboni, S Giri	01/01/2023
Oncologists' Perspectives on Individualizing Dose Selection for Patients With Metastatic Cancer. JCO oncology practice	RB Jimenez, C Schenkel, LA Levit, B Hu, XJ Lei, RD Harvey, VA Morrison, T Pollastro, D Waterhouse, C Weekes, GR Williams, S Bruinooge, E Garrett-Mayer, J Peppercorn	11/01/2022
Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors. Investigational new drugs	X Zhou, U Vaishampayan, D Mahalingam, RD Harvey, KY Chung, F Sedarati, C Dong, DV Faller, K Venkatakrishnan, N Gupta	10/01/2022
Webinar as an Informational Resource on Trastuzumab Biosimilars: Planning, Promotion, Execution, and Evaluation. Cancer investigation	EL Papautsky, M Carlson, SM Johnson, H Montague, L Valero, DJ Attai, RD Harvey, GH Lyman, M Lustberg	08/01/2022
Daratumumab for the Treatment of Multiple Myeloma: A Review of Clinical Applicability and Operational Considerations. The Annals of pharmacotherapy	JR Arnall, KT Maples, RD Harvey, DC Moore	08/01/2022
Enabling the Sharing of Single-Dose Vials Through Risk Mitigation to Decrease Financial Toxicity. JAMA oncology	DA Goldstein, RD Harvey, KKW Chan	06/01/2022
Call to Action for Improving Oral Anticancer Agent Adherence. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	LA Levit, S Arora, PG Kluetz, A Magnuson, A Rahman, RD Harvey	04/01/2022
Positive Practice Changes After the COVID-19 Pandemic: From the Advanced Practice Provider Perspective. Journal of the advanced practitioner in oncology	RD Harvey, A Begue, C Raine, R Yabroff	04/01/2022
A dose-escalation clinical trial of intranasal ketamine for uncontrolled cancer-related pain. Pharmacotherapy	V Singh, TW Gillespie, O Lane, B Spektor, AJ Zarrabi, K Egan, K Curseen, M Tsvetkova, JH Beumer, R Sniecinski, JW Shteamer, J Switchenko, RD Harvey	04/01/2022
Therapeutic Misconception about Research Procedures: Does a Simple Information Chart Improve Understanding? Ethics & human research	G Campbell, MD Dixon, M Lohani, J Cook, R Hianik, MC Thomson, E Abernethy, C Lewis, J Switchenko, RD Harvey, RD Pentz	03/01/2022
Impact of concurrent gabapentin or pregabalin with high-dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant. Pharmacotherapy	A Sivakumar, EB Bryson, KH Hall, KT Maples, S Goyal, NS Joseph, CC Hofmeister, JL Kaufman, S Lonial, AK Nooka, RD Harvey	03/01/2022
Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study. The Lancet. Oncology	DC Qian, T Kleber, B Brammer, KM Xu, JM Switchenko, JR Janopaul-Naylor, J Zhong, ML Yushak, RD Harvey, CM Paulos, DH Lawson, MK Khan, RR Kudchadkar, ZS Buchwald	12/01/2021
Prophylaxis and treatment strategies for optimizing chemotherapy relative dose intensity. Expert review of anticancer therapy	M Shayne, RD Harvey, GH Lyman	10/01/2021
LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial. Investigational new drugs	A Dowlati, RD Harvey, RD Carvajal, O Hamid, SJ Klempner, JSW Kauh, DA Peterson, D Yu, SC Chapman, AM Szpurka, M Carlsen, T Quinlan, R Wesolowski	08/01/2021
Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer. The Annals of pharmacotherapy	JM Seligson, AM Patron, MJ Berger, RD Harvey, ND Seligson	07/01/2021
Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	JJ Griggs, K Bohlke, EP Balaban, JJ Dignam, ET Hall, RD Harvey, DP Hecht, KA Klute, VA Morrison, TM Pini, GL Rosner, CD Runowicz, M Shayne, A Sparreboom, S Turner, C Zarwan, GH Lyman	06/20/2021
Tyrosine Kinase Inhibitors, Antibody-Drug Conjugates, and Proteolysis-Targeting Chimeras: The Pharmacology of Cutting-Edge Lung Cancer Therapies. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting	JW Carlisle, RD Harvey	06/01/2021
International Society of Oncology Pharmacy Practitioners (ISOPP) position statement: Role of the oncology pharmacy team in cancer care. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners	LM Holle, T Bilse, RM Alabelewe, PE Kintzel, EA Kandemir, CJ Tan, I Weru, CR Chambers, R Dobish, E Handel, K Tewthanom, M Saeteaw, LKM Dewi, R Schwartz, B Bernhardt, M Garg, A Chatterjee, P Manyau, A Chan, A Bayraktar-Ekincioglu, E Aras-Atik, RD Harvey, BR Goldspiel	06/01/2021
Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO-Friends of Cancer Research Joint Research Statement. Clinical cancer research : an official journal of the American Association for Cancer Research	ES Kim, TS Uldrick, C Schenkel, SS Bruinooge, RD Harvey, A Magnuson, A Spira, JL Wade, MD Stewart, DM Vega, JA Beaver, AM Denicoff, G Ison, SP Ivy, S George, RP Perez, PA Spears, WD Tap, RL Schilsky	05/01/2021
Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non-Small Cell Lung Cancer: Real-World Analysis of Select ASCO-Friends Recommendations. Clinical cancer research : an official journal of the American Association for Cancer Research	RD Harvey, SS Bruinooge, L Chen, E Garrett-Mayer, W Rhodes, E Stepanski, TS Uldrick, G Ison, S Khozin, WS Rubinstein, C Schenkel, RS Miller, GA Komatsoulis, RL Schilsky, ES Kim	05/01/2021
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Washout Period and Concomitant Medication Work Group. Clinical cancer research : an official journal of the American Association for Cancer Research	RD Harvey, KF Mileham, V Bhatnagar, JR Brewer, A Rahman, C Moravek, AS Kennedy, EA Ness, EC Dees, SP Ivy, SW Ebbinghaus, C Schenkel, TS Uldrick	05/01/2021
FDA Oncology Center of Excellence Project Renewal: Engaging the Oncology Community to Update Product Labeling for Older Oncology Drugs. Clinical cancer research : an official journal of the American Association for Cancer Research	PG Kluetz, P Keegan, GD Demetri, K Thornton, J Sul, J Kim, H Katzen, LB Burke, RD Harvey, E Alebachew, S Agrawal, A Nair, M Donoghue, WF Pierce, SS Shord, JJ Gao, R Pazdur	02/15/2021
Phase Ib Study of the Histone Deacetylase 6 Inhibitor Citarinostat in Combination With Paclitaxel in Patients With Advanced Solid Tumors. Frontiers in oncology	MS Gordon, GI Shapiro, J Sarantopoulos, D Juric, B Lu, A Zarotiadou, JN Connarn, Y Le Bruchec, CD Dumitru, RD Harvey	01/01/2021
Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. Clinical lymphoma, myeloma & leukemia	JL Kaufman, R Mina, JJ Shah, JP Laubach, AK Nooka, C Lewis, C Gleason, C Sharp, RD Harvey, LT Heffner, P Richardson, S Lonial, RZ Orlowski	12/01/2020
Current developments in the combination therapy of relapsed/refractory multiple myeloma. Expert review of anticancer therapy	KT Maples, NS Joseph, RD Harvey	12/01/2020
Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study. Clinical cancer research : an official journal of the American Association for Cancer Research	RM Connolly, E Laille, U Vaishampayan, V Chung, K Kelly, A Dowlati, OB Alese, RD Harvey, P Haluska, LL Siu, S Kummar, R Piekarz, SP Ivy, NM Anders, M Downs, A O'Connor, A Scardina, J Saunders, GL Rosner, MA Carducci, MA Rudek	10/15/2020
Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma. British journal of cancer	RD Harvey, BC Carthon, C Lewis, MS Hossain, C Zhang, Z Chen, WB Harris, OB Alese, W Shaib, MA Bilen, DH Lawson, C Wu, CE Steuer, BF El-Rayes, FR Khuri, S Lonial, EK Waller, SS Ramalingam, TK Owonikoko	10/01/2020
Pack-splitting to improve cost-effectiveness of oral agents in oncology. Clinical advances in hematology & oncology : H&O	RD Harvey	10/01/2020
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors. Journal for immunotherapy of cancer	AR Razak, JM Cleary, V Moreno, M Boyer, E Calvo Aller, W Edenfield, J Tie, RD Harvey, A Rutten, MA Shah, AJ Olszanski, D Jäger, N Lakhani, DP Ryan, E Rasmussen, G Juan, H Wong, N Soman, MD Smit, D Nagorsen, KP Papadopoulos	10/01/2020
Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners	RD Harvey, VR Adams, T Beardslee, P Medina	09/01/2020
Reply to Body fat indices and survival in immunotherapy-treated patients with cancer. Cancer	DJ Martini, Y Liu, VA Master, RD Harvey, MA Bilen	07/01/2020
Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an American Society of Clinical Oncology Survey. JCO oncology practice	DM Waterhouse, RD Harvey, P Hurley, LA Levit, ES Kim, HD Klepin, KF Mileham, G Nowakowski, C Schenkel, C Davis, SS Bruinooge, RL Schilsky	07/01/2020
A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research	TK Owonikoko, RD Harvey, B Carthon, Z Chen, C Lewis, H Collins, C Zhang, DH Lawson, OB Alese, MA Bilen, GL Sica, CE Steuer, WL Shaib, C Wu, WB Harris, M Akce, RR Kudchagkar, BF El-Rayes, S Lonial, SS Ramalingam, FR Khuri	06/01/2020
The Role of Pharmacists in Managing Adverse Events Related to Immune Checkpoint Inhibitor Therapy. Journal of pharmacy practice	P Medina, KD Jeffers, VA Trinh, RD Harvey	06/01/2020
In Reply. The oncologist	MA Bilen, VA Master, RD Harvey	05/01/2020
Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	MJ Markham, K Wachter, N Agarwal, MM Bertagnolli, SM Chang, W Dale, CSM Diefenbach, C Rodriguez-Galindo, DJ George, TD Gilligan, RD Harvey, ML Johnson, RJ Kimple, MA Knoll, N LoConte, RG Maki, JL Meisel, JA Meyerhardt, NA Pennell, GB Rocque, MS Sabel, RL Schilsky, BJ Schneider, WD Tap, RG Uzzo, SN Westin	04/01/2020
Precision Oncology Comes of Age: Tumor-Agnostic Approaches. Journal of the advanced practitioner in oncology	C Lewis, RD Harvey	04/01/2020
Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs. The oncologist	EP Balogh, AB Bindman, SG Eckhardt, S Halabi, RD Harvey, I Jaiyesimi, R Miksad, HL Moses, SJ Nass, RL Schilsky, S Sun, JM Torrente, KE Warren	03/01/2020
Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy. The oncologist	MA Bilen, DJ Martini, Y Liu, JM Shabto, JT Brown, M Williams, AI Khan, A Speak, C Lewis, H Collins, HT Kissick, BC Carthon, M Akce, WL Shaib, OB Alese, RN Pillai, CE Steuer, CS Wu, DH Lawson, RR Kudchadkar, BF El-Rayes, SS Ramalingam, TK Owonikoko, RD Harvey, VA Master	03/01/2020
Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials. Cancer	DJ Martini, MR Kline, Y Liu, JM Shabto, MA Williams, AI Khan, C Lewis, H Collins, M Akce, HT Kissick, BC Carthon, WL Shaib, OB Alese, RN Pillai, CE Steuer, CS Wu, DH Lawson, RR Kudchadkar, BF El-Rayes, SS Ramalingam, TK Owonikoko, RD Harvey, VA Master, MA Bilen	02/01/2020
New and Worsening Long-term Immune-Related Adverse Events with PD-1/PD-L1 Pathway Agents in Patients with Cancer. Pharmacotherapy	KH Hall, Y Liu, C Jiang, RD Harvey	02/01/2020
Impact of Disease and Treatment Response in Drug-Drug Interaction Studies: Osimertinib and Simvastatin in Advanced Non-Small Cell Lung Cancer. Clinical and translational science	K Vishwanathan, M Cantarini, K So, E Masson, J Fetterolf, SS Ramalingam, RD Harvey	01/01/2020
Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies. Cancer chemotherapy and pharmacology	LJ Appleman, JH Beumer, Y Jiang, Y Lin, F Ding, S Puhalla, L Swartz, TK Owonikoko, R Donald Harvey, R Stoller, DP Petro, HA Tawbi, A Argiris, S Strychor, M Pouquet, B Kiesel, AP Chen, D Gandara, CP Belani, E Chu, SS Ramalingam	12/01/2019
Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials. Investigational new drugs	DJ Martini, Y Liu, JM Shabto, C Lewis, MR Kline, H Collins, M Akce, HT Kissick, BC Carthon, WL Shaib, OB Alese, RN Pillai, CE Steuer, CS Wu, DH Lawson, RR Kudchadkar, VA Master, BF El-Rayes, SS Ramalingam, TK Owonikoko, RD Harvey, MA Bilen	12/01/2019
A Cost-Focused Alternative Cancer Medication Dispensing Strategy-"Pack Splitting". JAMA oncology	RD Harvey, MJ Ratain	12/01/2019
Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy. BMC cancer	MA Bilen, JM Shabto, DJ Martini, Y Liu, C Lewis, H Collins, M Akce, H Kissick, BC Carthon, WL Shaib, OB Alese, CE Steuer, C Wu, DH Lawson, R Kudchadkar, VA Master, B El-Rayes, SS Ramalingam, TK Owonikoko, RD Harvey	08/29/2019
A non-lethal malarial infection results in reduced drug metabolizing enzyme expression and drug clearance in mice. Malaria journal	SM Mimche, CM Lee, KH Liu, PN Mimche, RD Harvey, TJ Murphy, BA Nyagode, DP Jones, TJ Lamb, ET Morgan	07/12/2019
Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours. British journal of clinical pharmacology	H Faessel, J Nemunaitis, TM Bauer, AC Lockhart, DV Faller, F Sedarati, X Zhou, K Venkatakrishnan, RD Harvey	07/01/2019
Reply to African American patients may or may not have poorer response rates after monoclonal antibody treatment: Overreliance on P values in underpowered studies. Cancer	RD Harvey, C Zhang, S Lonial, JL Kaufman, Z Chen	07/01/2019
Reply to Tumor-associated macrophages: "Good cop-bad cop". Cancer	MA Bilen, HT Kissick, RD Harvey	06/01/2019
Pharmacokinetic Study of Osimertinib in Cancer Patients with Mild or Moderate Hepatic Impairment. The Journal of pharmacology and experimental therapeutics	E Grande, RD Harvey, B You, JF Batlle, H Galbraith, J Sarantopoulos, SS Ramalingam, H Mann, K So, M Johnson, K Vishwanathan	05/01/2019
Safety of Intranasal Ketamine for Reducing Uncontrolled Cancer-Related Pain: Protocol of a Phase I/II Clinical Trial. JMIR research protocols	JW Shteamer, RD Harvey, B Spektor, K Curseen, K Egan, Z Chen, TW Gillespie, RM Sniecinski, V Singh	04/30/2019
Phase IB Study of Induction Chemotherapy With XELOX, Followed by Radiation Therapy, Carboplatin, and Everolimus in Patients With Locally Advanced Esophageal Cancer. American journal of clinical oncology	NF Saba, S Force, C Staley, F Fernandez, F Willingham, A Pickens, K Cardona, Z Chen, L Goff, D Cardin, E Lambright, J Nesbitt, A Krasinskas, K Higgins, RD Harvey, T Owonikoko, SS Ramalingam, DM Shin, JJ Beitler, BF El-Rayes, S Salaria, W El-Rifai, J Landry, AB Chakravarthy	04/01/2019
Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor. Clinical pharmacokinetics	N Gupta, MJ Hanley, C Xia, R Labotka, RD Harvey, K Venkatakrishnan	04/01/2019
Incidence and management of adverse events associated with panobinostat in the treatment of relapsed/refractory multiple myeloma. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners	DC Moore, JR Arnall, RD Harvey	04/01/2019
Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies. British journal of clinical pharmacology	Y Ou, Y Xu, L Gore, RD Harvey, A Mita, KP Papadopoulos, Z Wang, RE Cutler, DE Pinchasik, AM Tsimberidou	03/01/2019
Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors. Investigational new drugs	AC Lockhart, TM Bauer, C Aggarwal, CB Lee, RD Harvey, RB Cohen, F Sedarati, TK Nip, H Faessel, AB Dash, BJ Dezube, DV Faller, A Dowlati	02/01/2019
Managing Drug Interactions With Oral Anticancer Agents: Signals, Noise, and Echoes. Journal of oncology practice	RD Harvey	02/01/2019
Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study. Blood cancer journal	JL Kaufman, R Mina, AJ Jakubowiak, TL Zimmerman, JJ Wolf, C Lewis, C Gleason, C Sharp, T Martin, LT Heffner, AK Nooka, RD Harvey, S Lonial	01/04/2019
The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy. Cancer	MA Bilen, DJ Martini, Y Liu, C Lewis, HH Collins, JM Shabto, M Akce, HT Kissick, BC Carthon, WL Shaib, OB Alese, RN Pillai, CE Steuer, CS Wu, DH Lawson, RR Kudchadkar, BF El-Rayes, VA Master, SS Ramalingam, TK Owonikoko, RD Harvey	01/01/2019
Academic oncology clinicians' understanding of biosimilars and information needed before prescribing. Therapeutic advances in medical oncology	JW Cook, MK McGrath, MD Dixon, JM Switchenko, RD Harvey, RD Pentz	01/01/2019
Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin. British journal of clinical pharmacology	RD Harvey, NR Aransay, N Isambert, JS Lee, T Arkenau, J Vansteenkiste, PA Dickinson, K Bui, D Weilert, K So, K Thomas, K Vishwanathan	12/01/2018
Accelerating anticancer drug development - opportunities and trade-offs. Nature reviews. Clinical oncology	SJ Nass, ML Rothenberg, R Pentz, H Hricak, A Abernethy, K Anderson, AW Gee, RD Harvey, S Piantadosi, MM Bertagnolli, D Schrag, RL Schilsky	12/01/2018
Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whites. Cancer	S Chehab, C Zhang, EH Panjic, Z Chen, JL Kaufman, S Lonial, A Nooka, RD Harvey	11/15/2018
Rationale, Opportunities, and Reality of Biosimilar Medications. The New England journal of medicine	GH Lyman, R Zon, RD Harvey	08/16/2018
Reply to S.D. Lucio. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	GH Lyman, R Zon, RD Harvey, RL Schilsky	07/10/2018
The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib. British journal of clinical pharmacology	K Vishwanathan, PA Dickinson, K So, K Thomas, YM Chen, J De Castro Carpeño, AC Dingemans, HR Kim, JH Kim, MG Krebs, J Chih-Hsin Yang, K Bui, D Weilert, RD Harvey	06/01/2018
Rationale, Opportunities, and Reality of Biosimilar Medications. The New England journal of medicine	GH Lyman, R Zon, RD Harvey, RL Schilsky	05/24/2018
Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	RZ Szmulewitz, CJ Peer, A Ibraheem, E Martinez, MF Kozloff, B Carthon, RD Harvey, P Fishkin, WP Yong, E Chiong, C Nabhan, T Karrison, WD Figg, WM Stadler, MJ Ratain	05/10/2018
American Society of Clinical Oncology Statement: Biosimilars in Oncology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	GH Lyman, E Balaban, M Diaz, A Ferris, A Tsao, E Voest, R Zon, M Francisco, S Green, S Sherwood, RD Harvey, RL Schilsky	04/20/2018
Intranasal Ketamine and Its Potential Role in Cancer-Related Pain. Pharmacotherapy	V Singh, TW Gillespie, RD Harvey	03/01/2018
Race-, Age-, and Gender-Based Characteristics and Toxicities of Targeted Therapies on Phase I Trials. Oncology	TK Owonikoko, AK Busari, S Kim, Z Chen, A Akintayo, C Lewis, BC Carthon, OB Alese, BF El-Rayes, SS Ramalingam, RD Harvey	01/01/2018
A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours. British journal of cancer	KP Papadopoulos, BF El-Rayes, AW Tolcher, A Patnaik, DW Rasco, RD Harvey, PM LoRusso, JC Sachdev, G Abbadessa, RE Savage, T Hall, B Schwartz, Y Wang, J Kazakin, WL Shaib	11/21/2017
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction, Prior or Concurrent Malignancy, and Comorbidities Working Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	SM Lichtman, RD Harvey, MA Damiette Smit, A Rahman, MA Thompson, N Roach, C Schenkel, SS Bruinooge, P Cortazar, D Walker, L Fehrenbacher	11/20/2017
Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling. Clinical pharmacokinetics	N Gupta, PM Diderichsen, MJ Hanley, D Berg, H van de Velde, RD Harvey, K Venkatakrishnan	11/01/2017
Science of Biosimilars. Journal of oncology practice	RD Harvey	09/01/2017
A Pharmacokinetic and Safety Study of Trebananib, an Fc-Fusion Peptibody, in Patients With Advanced Solid Tumors and Varying Degrees of Renal Dysfunction. Clinical pharmacology and therapeutics	B Wu, LD Lewis, RD Harvey, E Rasmussen, E Gamelin, YN Sun, G Friberg, JL Koyner, A Dowlati, ML Maitland	08/01/2017
Phase 1 Study of CEP-37250/KHK2804, a Tumor-specific Anti-glycoconjugate Monoclonal Antibody, in Patients with Advanced Solid Tumors. Targeted oncology	MM Mita, J Nemunaitis, J Grilley-Olson, B El-Rayes, T Bekaii-Saab, RD Harvey, J Marshall, X Zhang, V Strout	12/01/2016
Preventing and Managing Toxicities of High-Dose Methotrexate. The oncologist	SC Howard, J McCormick, CH Pui, RK Buddington, RD Harvey	12/01/2016
Precision, accuracy, and resolution-Dose selection of oral anticancer agents. Cancer	TJ Beardslee, RD Harvey	11/15/2016
A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis. British journal of haematology	N Gupta, MJ Hanley, RD Harvey, A Badros, B Lipe, V Kukreti, J Berdeja, H Yang, AM Hui, M Qian, X Zhang, K Venkatakrishnan, A Chari	09/01/2016
Impact of Isotope Dilution Mass Spectrometry (IDMS) Standardization on Carboplatin Dose and Adverse Events. Pharmacotherapy	J Lawson, JM Switchenko, T McKibbin, R Donald Harvey	06/01/2016
Calcium and Cancer: Of Evil Humors and Innocent Bystanders. Journal of oncology practice	RD Harvey	05/01/2016
Navigating the Landscape of Molecular Testing and Targeted Treatment of Non-Small Cell Lung Cancer. Journal of the advanced practitioner in oncology	SK Padda, RD Harvey	04/01/2016
Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors. The oncologist	AJ Olszanski, DC Smith, LH Camacho, J Thompson, SS Ramalingam, RD Harvey, L Campos, D Ferry, S Tang, L Gao, H Safran	04/01/2016
Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research	J Sarantopoulos, GI Shapiro, RB Cohen, JW Clark, JS Kauh, GJ Weiss, JM Cleary, D Mahalingam, MD Pickard, HM Faessel, AJ Berger, K Burke, G Mulligan, BJ Dezube, RD Harvey	02/15/2016
Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research	JJ Shah, AJ Jakubowiak, OA O'Connor, RZ Orlowski, RD Harvey, MR Smith, D Lebovic, C Diefenbach, K Kelly, Z Hua, AJ Berger, G Mulligan, HM Faessel, S Tirrell, BJ Dezube, S Lonial	01/01/2016
Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes. Expert review of clinical pharmacology	PG Richardson, RD Harvey, JP Laubach, P Moreau, S Lonial, JF San-Miguel	01/01/2016
Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer. Oncotarget	SA Brodie, G Li, D Harvey, FR Khuri, PM Vertino, JC Brandes	10/13/2015
Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial. Transfusion	N Jagirdar, RD Harvey, A Nooka, C Flowers, J Kaufman, S Lonial, MJ Lechowicz, A Langston, C Lipscomb, C Gaylor, EK Waller	10/01/2015
Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer	R Baz, HM Lin, AM Hui, RD Harvey, K Colson, K Gallop, P Swinburn, J Laubach, D Berg, P Richardson	09/01/2015
Development and testing of a tool to assess patient preferences for phase I clinical trial participation. Psycho-oncology	RD Pentz, KA Hendershot, L Wall, TE White, SK Peterson, CB Thomas, J McCormick, MJ Green, C Lewis, ZL Farmer, FJ Hlubocky, T Dossul, MD Dixon, Y Liu, JM Switchenko, C Salvador, TK Owonikoko, RD Harvey, FR Khuri	07/01/2015
A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research	TK Owonikoko, SS Ramalingam, DL Miller, SD Force, GL Sica, J Mendel, Z Chen, A Rogatko, M Tighiouart, RD Harvey, S Kim, NF Saba, A Pickens, M Behera, RW Fu, MR Rossi, WF Auffermann, WE Torres, R Bechara, X Deng, SY Sun, H Fu, AA Gal, FR Khuri	04/15/2015
Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patients. Cancer	MS Barbee, A Nooka, JL Kaufman, S Kim, Z Chen, LT Heffner, S Lonial, RD Harvey	03/15/2015
Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck. Cancer	NF Saba, SJ Hurwitz, K Magliocca, S Kim, TK Owonikoko, D Harvey, SS Ramalingam, Z Chen, J Rogerio, J Mendel, SA Kono, C Lewis, AY Chen, K Higgins, M El-Deiry, T Wadsworth, JJ Beitler, DM Shin, SY Sun, FR Khuri	12/15/2014
Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons	K Singh, L Stempora, RD Harvey, AD Kirk, CP Larsen, BR Blazar, LS Kean	12/01/2014
Cost effectiveness analysis of pharmacokinetically-guided 5-fluorouracil in FOLFOX chemotherapy for metastatic colorectal cancer. Clinical colorectal cancer	DA Goldstein, Q Chen, T Ayer, DH Howard, J Lipscomb, RD Harvey, BF El-Rayes, CR Flowers	12/01/2014
Pre-medications for cetuximab induced infusion reactions - commentary. Oral oncology	T McKibbin, R Donald Harvey, NF Saba	12/01/2014
Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee. Clinical lymphoma, myeloma & leukemia	N Raje, B Faiman, RD Harvey, SE Kurtin, S Lonial, SK Kumar, AD Cohen, MA Conde, SA Giralt, MS Recine, ER Tombler, E Stadtmauer, S Jagannath, KC Anderson	10/01/2014
Cancer, inflammation, and therapy: effects on cytochrome p450-mediated drug metabolism and implications for novel immunotherapeutic agents. Clinical pharmacology and therapeutics	RD Harvey, ET Morgan	10/01/2014
A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors. Oncotarget	HH Soliman, E Jackson, T Neuger, EC Dees, RD Harvey, H Han, R Ismail-Khan, S Minton, NN Vahanian, C Link, DM Sullivan, S Antonia	09/30/2014
Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood	PG Richardson, R Baz, M Wang, AJ Jakubowiak, JP Laubach, RD Harvey, M Talpaz, D Berg, G Liu, J Yu, N Gupta, A Di Bacco, AM Hui, S Lonial	08/14/2014
Immunologic and clinical effects of targeting PD-1 in lung cancer. Clinical pharmacology and therapeutics	RD Harvey	08/01/2014
Use of factor VIII after inhibitor clearance in patients with moderate haemophilia A: a case series. Haemophilia : the official journal of the World Federation of Hemophilia	DQ Tran, RD Harvey, SL Meeks, R Chapman, CL Kempton	07/01/2014
MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells. Blood	Y Gu, JL Kaufman, L Bernal, C Torre, SM Matulis, RD Harvey, J Chen, SY Sun, LH Boise, S Lonial	05/22/2014
Optimal dosing of melphalan as high-dose therapy before autologous hematopoietic stem cell transplantation in myeloma patients with solitary kidney: a case series. Clinical lymphoma, myeloma & leukemia	AK Nooka, RD Harvey, A Langston, H Collins, S Lonial, JL Kaufman	04/01/2014
Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib. Clinical pharmacology : advances and applications	RD Harvey	01/01/2014
Taxanes: vesicants, irritants, or just irritating? Therapeutic advances in medical oncology	MS Barbee, TK Owonikoko, RD Harvey	01/01/2014
In vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: a first-in-disease trial. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation	DT Koura, JT Horan, AA Langston, M Qayed, A Mehta, HJ Khoury, RD Harvey, Y Suessmuth, C Couture, J Carr, A Grizzle, HR Johnson, JA Cheeseman, JA Conger, J Robertson, L Stempora, BE Johnson, A Garrett, AD Kirk, CP Larsen, EK Waller, LS Kean	11/01/2013
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica	D Siegel, T Martin, A Nooka, RD Harvey, R Vij, R Niesvizky, AZ Badros, S Jagannath, L McCulloch, K Rajangam, S Lonial	11/01/2013
Novel role for the Streptococcus pneumoniae toxin pneumolysin in the assembly of biofilms. mBio	JR Shak, HP Ludewick, KE Howery, F Sakai, H Yi, RM Harvey, JC Paton, KP Klugman, JE Vidal	09/10/2013
Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation	RD Harvey, JL Kaufman, HR Johnson, A Nooka, L Vaughn, CR Flowers, HJ Khoury, MJ Lechowicz, AA Langston, S Lonial, EK Waller	09/01/2013
Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferences. The Annals of pharmacotherapy	MS Barbee, RD Harvey, S Lonial, JL Kaufman, NM Wilson, T McKibbin, DA Hutcherson, M Surati, K Valla, KS Shah	09/01/2013
Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. Clinical cancer research : an official journal of the American Association for Cancer Research	SI Shibata, V Chung, TW Synold, JA Longmate, AB Suttle, LH Ottesen, HJ Lenz, S Kummar, RD Harvey, AL Hamilton, BH O'Neil, J Sarantopoulos, P LoRusso, MA Rudek, A Dowlati, DL Mulkerin, CP Belani, L Gandhi, SC Lau, SP Ivy, EM Newman	07/01/2013
Bortezomib administration with severe hyperbilirubinemia caused by hepatic plasma cell infiltration: a case report. Clinical lymphoma, myeloma & leukemia	N Wilson, M Surati, BF Walker, JL Kaufman, RD Harvey	04/01/2013
A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies. British journal of cancer	RD Harvey, TK Owonikoko, CM Lewis, A Akintayo, Z Chen, M Tighiouart, SS Ramalingam, MP Fanucchi, P Nadella, A Rogatko, DM Shin, B El-Rayes, FR Khuri, JS Kauh	03/05/2013
Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	SS Ramalingam, TK Owonikoko, M Behera, J Subramanian, NF Saba, SA Kono, AA Gal, G Sica, RD Harvey, Z Chen, CM Klass, DM Shin, H Fu, SY Sun, R Govindan, FR Khuri	03/01/2013
Tools to optimize the functionality of a leukemia clinical trial team. Leukemia & lymphoma	B Bethelmie-Bryan, K Lord, S Holloway, F Safavi, M Shepard, S Rogers, RD Harvey, K Rodger, EK Waller, B El-Rayes, M Arellano, HJ Khoury	01/01/2013
Therapeutic misconception, misestimation, and optimism in participants enrolled in phase 1 trials. Cancer	RD Pentz, M White, RD Harvey, ZL Farmer, Y Liu, C Lewis, O Dashevskaya, T Owonikoko, FR Khuri	09/15/2012
External quality assurance for image grading in the Scottish Diabetic Retinopathy Screening Programme. Diabetic medicine : a journal of the British Diabetic Association	KA Goatman, S Philip, AD Fleming, RD Harvey, KK Swa, C Styles, M Black, G Sell, N Lee, PF Sharp, JA Olson	06/01/2012
Research biopsies in phase I studies: views and perspectives of participants and investigators. IRB	RD Pentz, RD Harvey, M White, ZL Farmer, O Dashevskaya, Z Chen, C Lewis, TK Owonikoko, FR Khuri	01/01/2012
Withaferin A inhibits breast cancer invasion and metastasis at sub-cytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation. International journal of cancer	JT Thaiparambil, L Bender, T Ganesh, E Kline, P Patel, Y Liu, M Tighiouart, PM Vertino, RD Harvey, A Garcia, AI Marcus	12/01/2011
How uniform is cAMP signaling? Focus on "Systems analysis of GLP-1 receptor signaling in pancreatic β-cells". American journal of physiology. Cell physiology	RD Harvey	10/01/2011
Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies. Cancer	J Kauh, C Chanel-Vos, D Escuin, MP Fanucchi, RD Harvey, N Saba, DM Shin, A Gal, L Pan, M Kutner, SS Ramalingam, L Bender, A Marcus, P Giannakakou, FR Khuri	09/01/2011
A randomized clinical trial comparing granulocyte-colony-stimulating factor administration sites for mobilization of peripheral blood stem cells for patients with hematologic malignancies undergoing autologous stem cell transplantation. Transfusion	H Renfroe, M Arnold, L Vaughn, RD Harvey, E Hamilton, S Lonial, HJ Khoury, JL Kaufman, MJ Lechowicz, CR Flowers, EK Waller	08/01/2011
A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study. Clinical cancer research : an official journal of the American Association for Cancer Research	S Lonial, J Kaufman, M Tighiouart, A Nooka, AA Langston, LT Heffner, C Torre, S McMillan, H Renfroe, RD Harvey, MJ Lechowicz, HJ Khoury, CR Flowers, EK Waller	10/15/2010
Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	SS Ramalingam, S Kummar, J Sarantopoulos, S Shibata, P LoRusso, M Yerk, J Holleran, Y Lin, JH Beumer, RD Harvey, SP Ivy, CP Belani, MJ Egorin	10/10/2010
Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. Cancer	SS Ramalingam, RD Harvey, N Saba, TK Owonikoko, J Kauh, DM Shin, SY Sun, S Strychor, M Tighiouart, MJ Egorin, H Fu, FR Khuri	08/15/2010
Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	WG Tong, R Chen, W Plunkett, D Siegel, R Sinha, RD Harvey, AZ Badros, L Popplewell, S Coutre, JA Fox, K Mahadocon, T Chen, P Kegley, U Hoch, WG Wierda	06/20/2010
Iron overload in myelodysplastic syndromes. Introduction. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists	RD Harvey, CA Fausel	04/01/2010
Myelodysplastic syndromes and the role of iron overload. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists	RD Harvey	04/01/2010
Through the looking glass: the evolution of erythropoiesis-stimulating agent use. Oncology (Williston Park, N.Y.)	RD Harvey, FR Khuri, JS Kauh	03/01/2010
Histological and genetic markers for non-small-cell lung cancer: customizing treatment based on individual tumor biology. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists	VR Adams, RD Harvey	01/01/2010
Commentary on Perrone et al.: 'vitamin C: not for breakfast anymore...if you have myeloma'. Leukemia	RD Harvey, J Nettles, B Wang, SY Sun, S Lonial	11/01/2009
Cytoplasmic cAMP concentrations in intact cardiac myocytes. American journal of physiology. Cell physiology	RV Iancu, G Ramamurthy, S Warrier, VO Nikolaev, MJ Lohse, SW Jones, RD Harvey	08/01/2008
PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma. Future oncology (London, England)	RD Harvey, S Lonial	12/01/2007
Novel therapeutic agents in the management of hemorrhage and thrombosis. Cardiovascular & hematological agents in medicinal chemistry	CL Kempton, RD Harvey, HR Roberts	10/01/2006
Intravenous immunoglobulin therapy: the process, the product, the patient, and the pocketbook. Introduction. Pharmacotherapy	RD Harvey	11/01/2005
The patient: Emerging clinical applications of intravenous immunoglobulin. Pharmacotherapy	RD Harvey	11/01/2005

Awards

Select awards and honors for Dr. Harvey include:

Award of Excellence, Hematology/Oncology Pharmacy Association (HOPA), 2018
James R. Eckman Award for Teaching Excellence, Emory School of Medicine Hematology and Medical Oncology Fellowship Program, 2014